

Migraine Drug Usage

Reference Number: RDF2296-24

Date of Response: 27/02/24

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

A. How many patients have been treated with the following drugs in the past 4 months:

Atogepant (Aquipta) – any disease

Erenumab (Aimovig) - any disease

Eptinezumab (Vyepiti) – any disease

Fremanezumab (Ajovy) - any disease

Galcanezumab (Emgality) - any disease

Rimegepant (Vydura) – any disease

Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY

Please see the Trust response below. Note we can only identify migraine from the ICD-10 coding G43 – Migraines:

<u><i>Drug</i></u>	<u><i>Patients treated</i></u>
<i>Atogepant (Aquipta) – any disease</i>	Nil
<i>Erenumab (Aimovig) - any disease</i>	125
<i>Eptinezumab (Vyepiti) – any disease</i>	Nil
<i>Fremanezumab (Ajovy) - any disease</i>	115
<i>Galcanezumab (Emgality) - any disease</i>	17
<i>Rimegepant (Vydura) – any disease</i>	54
<i>Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY</i>	140

B. How many patients have you treated in the last 4 months for chronic migraine (15+ headache days per month) and episodic migraine (4-15 headache days per month) with the following drugs:

Please see the Trust response below. Note we can only identify migraine from the ICD-10 coding G43 – Migraines:

<u>Drug</u>	<u>Patients treated – Migraine ICD-10 G43)</u>
<i>Atogepant</i>	Nil
<i>Erenumab</i>	57
<i>Eptinezumab</i>	Nil
<i>Fremanezumab</i>	83
<i>Galcanezumab</i>	13
<i>Rimegepant</i>	34
<i>Botulinum Toxin</i>	140

C. Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?

Yes, where possible. The review appointment at 12 Months is for that purpose.